Physician profile
Thomas Rumble
NPI 1306823323
$2,359.06
in general payments reported to CMS, 2019-2025
14 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $108 · 2021: $156 · 2022: $642 · 2023: $423 · 2024: $359 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.04 |
| Education | $187.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $955.48 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $358.30 | 2019-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $254.76 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $197.20 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $154.21 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $128.96 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $59.44 | 2021-2023 | Vraylar |
| Lundbeck LLC | $52.28 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $48.67 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $46.37 | 2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $32.69 | 2022 | |
| Allergan, INC. | $29.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.48 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rumble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.